{"id":741181,"date":"2023-03-20T08:24:18","date_gmt":"2023-03-20T12:24:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\/"},"modified":"2023-03-20T08:24:18","modified_gmt":"2023-03-20T12:24:18","slug":"ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\/","title":{"rendered":"AC Immune at AD\/PD\u2122 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <strong>AC Immune<\/strong><br \/>\n        <strong>at AD\/PD<\/strong><br \/>\n        <strong>\u2122 202<\/strong><br \/>\n        <strong>3<\/strong><br \/>\n        <strong>to <\/strong><br \/>\n        <strong>Present<\/strong><br \/>\n        <strong>New Clinical and Preclinical Data f<\/strong><br \/>\n        <strong>rom<\/strong><br \/>\n        <strong>its Precision Medicine Pipeline<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:left\">Ten presentations at the International Conference on Alzheimer\u2019s &amp; Parkinson\u2019s Diseases (AD\/PD<sup>TM<\/sup>)<\/li>\n<li style=\"text-align:left\">AC Immune\u2019s Chief Medical Officer to participate in expert forum on immunotherapies in Alzheimer\u2019s disease<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Lausanne, Switzerland,<\/strong><br \/>\n        <strong>March<\/strong><br \/>\n        <strong>20<\/strong><br \/>\n        <strong>,<\/strong><br \/>\n        <strong>202<\/strong><br \/>\n        <strong>3<\/strong> \u2013 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that ten presentations will be delivered at the International Conference on Alzheimer\u2019s &amp; Parkinson\u2019s Diseases (AD\/PD<sup>TM<\/sup> 2023), taking place in Gothenburg, Sweden, and virtually, on March 28 \u2013 April 1, 2023. In addition, Johannes Streffer, M.D., Chief Medical Officer of AC\u00a0Immune, will join an expert panel to discuss the latest developments in immunotherapies in Alzheimer\u2019s disease.<\/p>\n<p align=\"justify\">\n        <strong>Andrea Pfeifer,<\/strong><br \/>\n        <strong> Ph<\/strong><br \/>\n        <strong>.<\/strong><br \/>\n        <strong>D<\/strong><br \/>\n        <strong>.<\/strong><br \/>\n        <strong>,<\/strong><br \/>\n        <strong> CEO of AC Immune SA, commented:<\/strong> \u201cThe ten presentations during this AD\/PD<sup>TM<\/sup> conference demonstrate AC Immune\u2019s progress towards our over-arching goal, which is to shift the treatment paradigm towards Precision Medicine and disease prevention. As our clinical programs in Alzheimer\u2019s and Parkinson\u2019s diseases are advancing, we are solidifying our position as a leading developer of vaccines for neurodegenerative diseases. AC Immune\u2019s cutting-edge therapeutic and diagnostic research programs pursuing multiple validated molecular targets, highlight the breadth of our pipeline. These will drive our differentiated Precision Medicine approach in neurodegeneration and become substantial value creating catalysts.\u201d<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>AC Immune p<\/u><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <u>resentations<\/u><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <u>at <\/u><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <u>AD\/PD<sup>TM<\/sup><\/u><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <u>202<\/u><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <u>3<\/u><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <u> (all times are CE<\/u><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <u>S<\/u><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <u>T)<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Roundtable discussion<\/strong><br \/>\n        <br \/>\n        <em>Forum 02: <\/em><br \/>\n        <em>I<\/em><br \/>\n        <em>mmunotherapies in <\/em><br \/>\n        <em>AD<\/em><br \/>\n        <em>: from basics to approval<\/em><br \/>\n        <br \/>Date: Wed, 29.03.2023 | 03:55\u00a0PM &#8211; 04:55\u00a0PM | Hall C<br \/>Panelist: Forum discussion with Johannes Streffer, M.D., (AC Immune)<\/p>\n<p align=\"justify\">\n        <strong>Active immunotherapy<\/strong><br \/>\n        <br \/>\n        <em>A<\/em><br \/>\n        <em>BATE<\/em><br \/>\n        <em> study \u2013 <\/em><br \/>\n        <em>U<\/em><br \/>\n        <em>tilizing biomarker-based development for optimized <\/em><br \/>\n        <em>ACI<\/em><br \/>\n        <em>-24, a novel candidate vaccine for the treatment and prevention of <\/em><br \/>\n        <em>A<\/em><br \/>\n        <em>lzheimer\u2019s <\/em><br \/>\n        <em>disease<\/em><br \/>\n        <br \/>Date: Sat, 01.04.2023 | 05:55 PM &#8211; 06:10 PM | Hall G3<br \/>Presenter: Oral presentation by Johannes Streffer, M.D., (AC Immune)<\/p>\n<p align=\"justify\">\n        <em>Beneficial effect of <\/em><br \/>\n        <em>ACI<\/em><br \/>\n        <em>-24 vaccination on <\/em><br \/>\n        <em>A<\/em><br \/>\n        <em>beta plaque pathology and microglial phenotypes in an amyloidosis mouse model<\/em><br \/>\n        <br \/>Date: Sat, 01.04.2023 | 09:25 AM &#8211; 09:40 AM | Hall G4<br \/>Presenter: Oral presentation by Sabina Tahirovic, Ph.D., (German Center for Neurodegenerative Diseases)<\/p>\n<p align=\"justify\">\n        <em>A novel anti-amyloid beta (<\/em><br \/>\n        <em>A<\/em><br \/>\n        <em>beta) vaccine, a potent immunotherapy for the prevention and treatment of <\/em><br \/>\n        <em>A<\/em><br \/>\n        <em>lzheimer\u2019s disease in <\/em><br \/>\n        <em>D<\/em><br \/>\n        <em>own syndrome<\/em><br \/>\n        <br \/>Date: Sat., 01.04.2023 | 07:00 AM \u2013 08:30 AM | OD349 \/ #1688<br \/>Presenter: On-demand symposium by Emma Fiorini, Ph.D. (AC Immune)<\/p>\n<p align=\"justify\">\n        <em>Vac<\/em><br \/>\n        <em>SY<\/em><br \/>\n        <em>n<\/em><br \/>\n        <em> study design \u2013 biomarker-based development for <\/em><br \/>\n        <em>ACI<\/em><br \/>\n        <em>-7104, a novel candidate vaccine for the treatment and prevention of <\/em><br \/>\n        <em>P<\/em><br \/>\n        <em>arkinson\u2019s disease<\/em><br \/>\n        <br \/>Date: Available online from Tue, 28.03.2023 | Poster P0313 \/ #1791<br \/>Presenter: On demand presentation by Dymitr Kostrica, Ph.D. (AC Immune)<\/p>\n<p align=\"justify\">\n        <strong>Passive<\/strong><br \/>\n        <strong> immunotherapy<\/strong><br \/>\n        <br \/>\n        <em>Antibody-mediated inhibition of <\/em><br \/>\n        <em>ASC <\/em><br \/>\n        <em>attenuates inflammasome activation in vitro and in a mouse model of <\/em><br \/>\n        <em>demyelination<\/em><br \/>\n        <br \/>Date: Wed, 29.03.2023 | 04:15 PM &#8211; 04:30 PM | Hall G4<br \/>Presenter: Oral presentation by Davide Basco, Ph.D. (AC Immune)<\/p>\n<p align=\"justify\">\n        <em>Development of <\/em><br \/>\n        <em>TDP<\/em><br \/>\n        <em>-43 immunotherapy blocking transmission of seeding-competent species from <\/em><br \/>\n        <em>ALS\/FTD<\/em><br \/>\n        <br \/>Date: Thu, 30.03.2023 | 06:05 PM &#8211; 06:20 PM | Hall G3<br \/>Presenter: Oral presentation by Tariq Afroz, Ph.D. (AC Immune)<\/p>\n<p align=\"justify\">\n        <strong>Small molecules<\/strong><br \/>\n        <br \/>\n        <em>Discovery of therapeutic small molecules targeting alpha-synuclein aggregation<\/em><br \/>\n        <br \/>Date: Fri, 31.03.2023 | 07:00 AM \u2013 08:30 AM | OD209 \/ #1442<br \/>Presenter: On demand presentation by Elpida Tsika, Ph.D. (AC Immune)<\/p>\n<p align=\"justify\">\n        <strong>Diagnostics &amp; biomarkers<\/strong><br \/>\n        <br \/>\n        <em>Discovery and in<\/em><br \/>\n        <em>i<\/em><br \/>\n        <em>tial clinical evaluation<\/em><br \/>\n        <em>[18<\/em><br \/>\n        <em>F<\/em><br \/>\n        <em>]<\/em><br \/>\n        <em>ACI<\/em><br \/>\n        <em>-12589, a novel and promising <\/em><br \/>\n        <em>PET<\/em><br \/>\n        <em>-tracer for a-synuclein<\/em><br \/>\n        <br \/>Date: Thu, 30.03.2023 | 09:40 AM &#8211; 09:55 AM | Hall F4+F5<br \/>Presenter: Oral presentation by Francesca Capotosti, Ph.D. (AC Immune)<\/p>\n<p align=\"justify\">\n        <em>Compartmentalization of plasma <\/em><br \/>\n        <em>TDP<\/em><br \/>\n        <em>-43 in platelets: implications for <\/em><br \/>\n        <em>TDP<\/em><br \/>\n        <em>-43-related biomarker development<\/em><br \/>\n        <br \/>Date: Thu, 30.03.2023 | 02:05 PM &#8211; 02:20 PM | Hall G3<br \/>Presenter: Oral presentation by Ruth Luthi-Carter, Ph.D. (AC Immune)<\/p>\n<p align=\"justify\">\n        <em>Optimization of affinity, selectivity and pharmacokinetic profile of <\/em><br \/>\n        <em>TDP<\/em><br \/>\n        <em>-43<\/em><br \/>\n        <em> PET<\/em><br \/>\n        <em>ligands<\/em><br \/>\n        <br \/>Date: Available online from Tue, 28.03.2023 | Poster P0994 \/ #979<br \/>Presenter: On demand presentation by Tamara Seredenina, Ph.D. (AC Immune)<\/p>\n<p align=\"justify\">\n        <strong>About AC Immune SA <\/strong><br \/>\n        <br \/>AC Immune SA\u00a0is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer\u2019s disease, Parkinson\u2019s disease, and NeuroOrphan indications driven by misfolded proteins. The Company\u2019s two clinically validated technology platforms, SupraAntigen<sup>\u00ae<\/sup>\u00a0and Morphomer<sup>\u00ae<\/sup>, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3.\u00a0AC Immune\u00a0has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including\u00a0Genentech, a member of the Roche Group, Eli Lilly and Company, and\u00a0others, resulting in substantial non-dilutive funding to advance its proprietary programs and &gt;$3\u00a0billion\u00a0in potential milestone payments.<\/p>\n<p align=\"justify\">SupraAntigen<sup>\u00ae<\/sup>\u00a0is a registered trademark of\u00a0AC Immune SA\u00a0in the following territories: AU, EU, CH, GB, JP, RU, SG and\u00a0USA. Morphomer<sup>\u00ae<\/sup> is a registered trademark of\u00a0AC Immune SA\u00a0in CN, CH, GB, JP, KR, NO and RU.<\/p>\n<p align=\"justify\">The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.<\/p>\n<p align=\"justify\">\n        <strong>For further information, please contact:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:450pt;border-collapse:collapse\">\n<tr>\n<td style=\"width:281.4px;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Head of <\/strong><br \/>\n            <strong>Investor Relations<\/strong><br \/>\n            <strong> &amp; Corporate Communications<\/strong><br \/>\n            <br \/>Gary Waanders, Ph.D., MBA<br \/>AC Immune<br \/>Phone: +41 21 345 91 91<br \/>Email: <a href=\"mailto:gary.waanders@acimmune.com\" rel=\"nofollow noopener\" target=\"_blank\">gary.waanders@acimmune.com<\/a><\/p>\n<\/td>\n<td style=\"width:318.6px;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>U.S. Investors<\/strong><br \/>\n            <br \/>Corey Davis, Ph.D.<br \/>LifeSci Advisors<br \/>Phone: +1 212 915 2577 <br \/>Email: <a href=\"mailto:cdavis@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">cdavis@lifesciadvisors.com<\/a><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:281.4px;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>International Media<\/strong><br \/>\n            <br \/>Chris Maggos<br \/>Cohesion Bureau<br \/>Phone: +41 79 367 6254<br \/>Email: <a href=\"mailto:chris.maggos@cohesionbureau.com\" rel=\"nofollow noopener\" target=\"_blank\">chris.maggos@cohesionbureau.com<\/a><\/td>\n<td style=\"width:318.6px;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>Forward looking statements<\/strong><br \/>\n        <br \/>This press release contains statements that constitute \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune\u2019s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201cpotential,\u201d \u201coutlook\u201d or \u201ccontinue,\u201d and other comparable terminology. Forward-looking statements are based on management\u2019s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions \u201cItem 3. Key Information \u2013 Risk Factors\u201d and \u201cItem 5. Operating and Financial Review and Prospects\u201d in AC Immune\u2019s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.<\/p>\n<p \/>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/89c9cc20-7183-4f35-88b1-3d46950a0d62\" rel=\"noopener\">20230320-ADPD2023_curtain-raiser-FINAL<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5OTA0MSM0MDE1MTIwNjEjMjAyNTg3MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/YzZhNjFlZjktY2VhNC00YzM2LTllNWMtZmUzOTE1M2Y2Y2Y1LTEwMzc0NDM=\/tiny\/AC-Immune-SA.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AC Immune at AD\/PD \u2122 202 3 to Present New Clinical and Preclinical Data f rom its Precision Medicine Pipeline Ten presentations at the International Conference on Alzheimer\u2019s &amp; Parkinson\u2019s Diseases (AD\/PDTM) AC Immune\u2019s Chief Medical Officer to participate in expert forum on immunotherapies in Alzheimer\u2019s disease Lausanne, Switzerland, March 20 , 202 3 \u2013 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that ten presentations will be delivered at the International Conference on Alzheimer\u2019s &amp; Parkinson\u2019s Diseases (AD\/PDTM 2023), taking place in Gothenburg, Sweden, and virtually, on March 28 \u2013 April 1, 2023. In addition, Johannes Streffer, M.D., Chief Medical Officer of AC\u00a0Immune, will join an expert panel to discuss &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AC Immune at AD\/PD\u2122 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-741181","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AC Immune at AD\/PD\u2122 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AC Immune at AD\/PD\u2122 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AC Immune at AD\/PD \u2122 202 3 to Present New Clinical and Preclinical Data f rom its Precision Medicine Pipeline Ten presentations at the International Conference on Alzheimer\u2019s &amp; Parkinson\u2019s Diseases (AD\/PDTM) AC Immune\u2019s Chief Medical Officer to participate in expert forum on immunotherapies in Alzheimer\u2019s disease Lausanne, Switzerland, March 20 , 202 3 \u2013 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that ten presentations will be delivered at the International Conference on Alzheimer\u2019s &amp; Parkinson\u2019s Diseases (AD\/PDTM 2023), taking place in Gothenburg, Sweden, and virtually, on March 28 \u2013 April 1, 2023. In addition, Johannes Streffer, M.D., Chief Medical Officer of AC\u00a0Immune, will join an expert panel to discuss &hellip; Continue reading &quot;AC Immune at AD\/PD\u2122 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-20T12:24:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5OTA0MSM0MDE1MTIwNjEjMjAyNTg3MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AC Immune at AD\\\/PD\u2122 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline\",\"datePublished\":\"2023-03-20T12:24:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\\\/\"},\"wordCount\":1129,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc5OTA0MSM0MDE1MTIwNjEjMjAyNTg3MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\\\/\",\"name\":\"AC Immune at AD\\\/PD\u2122 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc5OTA0MSM0MDE1MTIwNjEjMjAyNTg3MQ==\",\"datePublished\":\"2023-03-20T12:24:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc5OTA0MSM0MDE1MTIwNjEjMjAyNTg3MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc5OTA0MSM0MDE1MTIwNjEjMjAyNTg3MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AC Immune at AD\\\/PD\u2122 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AC Immune at AD\/PD\u2122 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"AC Immune at AD\/PD\u2122 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline - Market Newsdesk","og_description":"AC Immune at AD\/PD \u2122 202 3 to Present New Clinical and Preclinical Data f rom its Precision Medicine Pipeline Ten presentations at the International Conference on Alzheimer\u2019s &amp; Parkinson\u2019s Diseases (AD\/PDTM) AC Immune\u2019s Chief Medical Officer to participate in expert forum on immunotherapies in Alzheimer\u2019s disease Lausanne, Switzerland, March 20 , 202 3 \u2013 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that ten presentations will be delivered at the International Conference on Alzheimer\u2019s &amp; Parkinson\u2019s Diseases (AD\/PDTM 2023), taking place in Gothenburg, Sweden, and virtually, on March 28 \u2013 April 1, 2023. In addition, Johannes Streffer, M.D., Chief Medical Officer of AC\u00a0Immune, will join an expert panel to discuss &hellip; Continue reading \"AC Immune at AD\/PD\u2122 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-20T12:24:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5OTA0MSM0MDE1MTIwNjEjMjAyNTg3MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AC Immune at AD\/PD\u2122 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline","datePublished":"2023-03-20T12:24:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\/"},"wordCount":1129,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5OTA0MSM0MDE1MTIwNjEjMjAyNTg3MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\/","name":"AC Immune at AD\/PD\u2122 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5OTA0MSM0MDE1MTIwNjEjMjAyNTg3MQ==","datePublished":"2023-03-20T12:24:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5OTA0MSM0MDE1MTIwNjEjMjAyNTg3MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5OTA0MSM0MDE1MTIwNjEjMjAyNTg3MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-at-ad-pd-2023-to-present-new-clinical-and-preclinical-data-from-its-precision-medicine-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AC Immune at AD\/PD\u2122 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/741181","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=741181"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/741181\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=741181"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=741181"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=741181"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}